The TRYPHAENA trial added carboplatin to anthracycline-free neoadjuvant chemotherapy, which yielded similar pCR and event-free survival (EFS) between both groups17, establishing the role of carboplatin in treating HER2 + BC. This evidence concerns the gene ERBB2 and breast cancer.